The New York Times: February 20, 2021. One month into his presidency, President Biden still has not named a candidate to head the Food and Drug Administration, a critical position at a time when new vaccines and coronavirus treatments are under the agency’s review. This has spurred a public lobbying campaign by supporters of the two apparent front-runners, Dr. Joshua Sharfstein, a former high-ranking F.D.A. official and Dr. Janet Woodcock, the acting commissioner.
Read More »Tag: Covid-19
New Trump Administration Policies for FDA Under Fire
Medscape, January 15, 2021. New policies will weaken regulations on medical products if the Trump administration passes them before leaving.
Read More »Congressman calls for FDA to continue vaccine trials
ABC, December 29, 2020. Rep. Llyod Doggett of Texas wrote to the FDA urging COVID-19 clinical trials to continue until they have more data.
Read More »Covid-19: Should vaccine trials be unblinded?
BMJ, December 29, 2020. Volunteers in COVID-19 vaccine studies want the vaccine, not placebos, but stopping studies early could be dangerous.
Read More »Dr. Diana Zuckerman’s Testimony on Moderna’s COVID Vaccine Before the FDA Advisory Committee
December 17, 2020: We need at least 1 year of blinded, randomized, controlled data. We agree that FDA should delay access to vaccines by members of the placebo group unless they are in priority populations.
Read More »